MedTrace Logo

DLBCL Interim Response Evaluation for Customised Therapy

NCT04226937 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-08-05

No results posted yet for this study

Summary

The aim of the DIRECT Study is to establish a robust pipeline to identify those patients with high-grade B cell lymphoma most suitable for novel agent clinical trials based upon genomic subtype and an integrated response evaluation determined early in first-line therapy.

Conditions

  • High-grade B-cell Lymphoma

Interventions

OTHER

Not Applicable as this is a translational, sample collection study.

Patients will take their normal standard of care treatment for their lymphoma, as per agreed with the patient's doctor. Blood samples will be collected at Baseline, during the first 3 cycles of Treatment, at End of Treatment, at 6- and 12-months after End of Treatment and at relapse/progression if applicable. Surplus Tissue biopsy will be collected at Baseline and at relapse/progression if applicable. In rare cases research-specific tissue biopsy may be collected if appropriate.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Cancer Research UK Cambridge Institute

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Daniel Hodson, PhD MRCP FRCPath · Cambridge University Hospitals NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-17
Primary Completion
2025-09-01
Completion
2025-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04226937 on ClinicalTrials.gov